Vali A. Papadimitrakopoulou, MD, and Heather A. Wakelee, MD, on Bevacizumab for Early-Stage NSCLC
2016 ASCO Annual Meeting
Vali A. Papadimitrakopoulou, MD, of MD Anderson Cancer Center, and Heather A. Wakelee, MD, of Stanford University, discuss findings on adjuvant chemotherapy with or without bevacizumab for early-stage non–small cell lung cancer, with outcomes based on chemotherapy subsets (Abstract 8507).
Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.
Nikhil Wagle, MD, of the Dana-Farber Cancer Institute, discusses the strides made in this national direct-to-patient initiative to accelerate genomics research (Abstract LBA1519).
Newly elected ASCO President Daniel F. Hayes, MD, of the University of Michigan Health System Comprehensive Cancer Center, talks about his vision for the society during his tenure.
Heinz-Josef Lenz, MD, of the University of Southern California, and Jonathan R. Strosberg, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discuss efficacy and safety results in patients with midgut neuroendocrine tumors treated with lutetium Lu-177 dotatate (Abstract 4005).
James Kochenderfer, MD, of the National Cancer Institute, discuss results of a small study on genetically modified CAR-T cells, which may well become a standard lymphoma treatment (Abstract LBA3010).